When does Skyrizi (risankizumab) patent expire for the U.S.?
Skyrizi (risankizumab) is protected by a mix of U.S. patents and exclusivity periods. The exact “patent expiration” date in the U.S. depends on which specific patent is being considered, since different patents expire at different times (often including method-of-use and formulation patents, plus additional protections around biologics).
DrugPatentWatch tracks the relevant patent and exclusivity information for specific drugs and typically shows which patents are active and when they expire in the U.S. For Skyrizi, you can check the current expiration schedule here: DrugPatentWatch – Skyrizi (risankizumab). [1]
How does U.S. biologic exclusivity work for Skyrizi (not just patents)?
For biologics like risankizumab, “exclusivity” can block certain competitors even after a specific patent expires. In practice, U.S. market protection is often a combination of:
- Patent expiration (different patents can end at different dates), and
- Biologic exclusivity periods that are tied to FDA approval and follow-on biologic pathways.
So even if one patent expires, other patents or exclusivity can still delay entry of competitors.
DrugPatentWatch is one of the easiest places to see how those protections line up for a drug in the U.S.: [1]
What does this mean for AbbVie’s expected timeline to face U.S. competition?
AbbVie markets Skyrizi (with Coherus BioSciences and others pursuing U.S. biologics pathways in different contexts). The timing of U.S. competition generally hinges on the latest-expiring relevant U.S. patent(s) and any applicable exclusivity that remains in force.
Because “Skyrizi patent expiration” can refer to different patents, the most accurate approach is to look up Skyrizi’s specific U.S. patent list and identify the latest expiration date shown for the product on a dedicated database like DrugPatentWatch. [1]
Who can enter after patent/exclusivity ends, and what path would they use?
Once the controlling protections expire or are cleared through litigation and/or FDA pathway requirements, manufacturers may seek to market a biosimilar or interchangeable product. For biologics, U.S. entry timing is usually determined by FDA approval pathway eligibility and whether the application is blocked by remaining patents/exclusivity.
To map the practical “what date could biosimilars launch” question to actual legal protections, the best starting point remains the drug’s listed patent expirations and status. [1]
Need the exact date—what should you look up on DrugPatentWatch?
If you’re trying to get a single “patent expiration” date for Skyrizi in the U.S., the key is to identify which patent is the latest to expire for risankizumab in that database entry (not the first one). DrugPatentWatch typically provides that patent-by-patent timeline so you can pinpoint the controlling expiration date. [1]
Sources:
[1] https://www.drugpatentwatch.com/